This Week's Top Stories Concerning ADHD Medication Pregnancy > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

The decision to stop or keep ADHD medications during pregnancy and nursing is a difficult decision for women suffering from the condition. There are few data on how long-term exposure may affect the pregnant fetus.

A recent study published in Molecular Psychiatry demonstrates that children exposed to adhd medications For adults with anxiety; bitetheass.com, medication during pregnancy do not develop neurological disorders like hearing loss or vision, febrile seizures, or IQ impairment. The authors acknowledge the need for higher-quality research.

Risk/Benefit Analysis

Women who are pregnant and take ADHD medication should consider the benefits of taking it against the possible risks to the foetus. Physicians don't have the information needed to make unequivocal recommendations but they can provide information on benefits and risks that can assist pregnant women in making informed choices.

A study published in Molecular Psychiatry concluded that women who were taking ADHD medication in early pregnancy were not at greater risk of fetal malformations or structural birth defects. Researchers conducted a large population-based case-control study to determine the prevalence of major structural birth defects in infants born to mothers who had taken stimulants in the early stages of pregnancy and those who had not. Pediatric cardiologists, clinical geneticists and other experts examined the cases to make sure that the classification was accurate and to reduce any bias.

The study of the researchers had some limitations. The most important issue was that they were unable to distinguish the effects of the medication from the underlying disorder. This makes it difficult for researchers to establish whether the small associations observed among the exposed groups were due to medication use or if they were confounded by co-morbidities. The researchers also did not look at long-term outcomes for the offspring.

The study revealed that infants whose mother had taken ADHD medication during pregnancy were at a slightly greater risk of being admitted to the neonatal care unit (NICU), compared to mothers who didn't take any medication during pregnancy or had stopped taking their medication before or during pregnancy. This increase was due to central nervous system-related disorders, and the higher risk of admission was not found to be influenced by the stimulant medication was used during pregnancy.

Women who used stimulant ADHD medication during pregnancy also had an elevated chance of having a caesarean delivery or having a baby born with low Apgar score (less than 7). These increases appeared to be unrelated to the type of medication used during pregnancy.

The research suggests that the small risk associated with the use of ADHD medications during early pregnancy may be offset by the higher benefit to both mother and child of continued treatment for the woman's disorder. Physicians should talk to their patients about this issue and try to help them improve coping skills which can lessen the effects of her disorder on her daily functioning and her relationships.

Medication Interactions

Many doctors are faced with the decision of whether to keep treatment or stop as more women are diagnosed with generic adhd medications. These decisions are frequently made without clear and authoritative evidence. Instead, physicians must consider their own expertise and experience, as well as the experiences of other physicians and the research on the subject.

The issue of risk for infants can be difficult to determine. Many of the studies on this subject are based on observations instead of controlled research and their conclusions are often contradictory. The majority of studies focus on live births, which can underestimate the teratogenic impact which can cause abortions or terminations of pregnancy. The study presented in the journal club addresses these shortcomings by analyzing both data on live and deceased births.

The conclusion is that while certain studies have demonstrated an association between ADHD medications and the risk of certain birth defects, other studies have found no connection, and most studies show a neutral or even slightly negative effect. In all cases an in-depth study of the risks and benefits should be conducted.

For a lot of women with ADHD who suffer from ADHD, the decision to stop taking medication is difficult if not impossible. In a recent article in Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can cause depression and feelings of loneliness. Furthermore, a loss of medication can affect the ability to do work-related tasks and safely drive that are crucial aspects of daily life for a lot of people with ADHD.

She suggests women who are uncertain about whether to keep or discontinue medication due to their pregnancy, consider educating family members, friends and colleagues about the condition, its effects on daily functioning, and on the advantages of continuing the current treatment regimen. It will also help a woman feel more confident in her decision. It is also worth noting that some medications can pass through the placenta so if a woman decides to stop her ADHD medication during pregnancy and breastfeeding, she must be aware that traces of the medication could be transferred to the child.

Birth Defects Risk

As the use and use of ADHD medications to treat the symptoms of attention deficit disorder hyperactivity disorder (ADHD), increases the concern over the potential adverse effects of the drugs on the fetuses. Recent research published in the journal Molecular Psychiatry has added to the body of knowledge on this topic. Researchers used two huge data sets to study more than 4.3 million pregnancies and determine whether stimulant medications caused birth defects. While the overall risk remains low, the researchers did find that first-trimester exposure to ADHD medications was linked to an increased risk of certain heart defects such as ventriculo-septal defect (VSD).

The authors of the study did not discover any link between early use of medication and other congenital anomalies such as facial deformities or club feet. The results are in the same vein as previous studies which showed an insignificant, but small increase in the number of cardiac malformations among women who began taking ADHD medication before the birth of their child. This risk increased in the latter half of pregnancy, when many women begin to discontinue their ADHD medication.

Women who took ADHD medication in the first trimester were more likely require a caesarean delivery or have a low Apgar after delivery, and have a baby that needed breathing assistance after birth. The authors of the study could not remove bias in selection since they limited their study to women who did not have any other medical conditions that could have contributed to the findings.

The researchers hope that their research will help inform the clinical decisions of doctors who see pregnant women. They advise that while the discussion of the benefits and risks is important but the decision to stop or continue treatment should be based on the woman's needs and the severity of her ADHD symptoms.

The authors warn that, although stopping the medication is an option to look into, it is not recommended due to the high prevalence of depression and other mental problems in women who are expecting or who have recently given birth. Additionally, research suggests that women who stop taking their medications will have a difficult time adjusting to a life without them once the baby is born.

Nursing

The responsibilities of a new mom can be overwhelming. Women with ADHD are often faced with a number types of adhd medication difficulties when they must deal with their symptoms, go to doctor appointments, prepare for the birth of a baby and adjust to new routines. This is why many women elect to continue taking their ADHD medications throughout pregnancy.

The risk to breastfeeding infant is minimal because the majority of stimulant medication passes through breast milk in low amounts. However, the amount of medication exposure to the newborn may differ based on dosage, frequency it is administered, and the time of day it is administered. Additionally, individual medications enter the infant's system differently through the gastrointestinal tract as well as breast milk, and the effect of this on a newborn isn't fully known.

Some doctors may decide to stop stimulant medication during a woman's pregnancy due to the lack of research. This is a difficult choice for the patient, who must weigh the benefit of continuing her medication with the potential dangers to the foetus. As long as more information is available, doctors can ask pregnant patients whether they have a background of ADHD or if they plan to take medication in the perinatal phase.

A growing number of studies have shown that most women can safely continue taking their ADHD medication while they are pregnant and nursing. In response, an increasing number of patients are opting to do so. They have found, in consultation with their doctor that the benefits of continuing their current medication outweigh risk.

It's important for women with ADHD who are considering breastfeeding to seek out a specialist psychiatrist's advice prior becoming pregnant. They should review their medications with their prescriber and discuss the advantages and disadvantages of continued treatment, including non-pharmacological management strategies. Psychoeducation is also necessary to help pregnant women suffering from ADHD understand the symptoms and underlying disorder. They should also be informed about treatment options and reinforce coping mechanisms. This should involve a multidisciplinary approach, which includes the GP as well as obstetricians, psychiatry and obstetricians. Pregnancy counseling should consist of a discussion of a treatment plan for the mother and the child, and monitoring for indicators of deterioration, and, if necessary, adjustments to the medication regime.